Inhibition of leukocyte-endothelial cell interactions and inflammation by peptides from a bacterial adhesin which mimic coagulation factor X.

Rozdzinski, E ; Sandros, J ; van der Flier, M ; Young, A ; Spellerberg, B ; Bhattacharyya, C ; Straub, J ; Musso, G ; Putney, S ; Starzyk, R (1995) Inhibition of leukocyte-endothelial cell interactions and inflammation by peptides from a bacterial adhesin which mimic coagulation factor X. Journal of Clinical Investigation, 95 (3). pp. 1078-1085. ISSN 0021-9738

[img] PDF
1MB

Official URL: http://doi.org/10.1172/JCI117754

Related URL: http://dx.doi.org/10.1172/JCI117754

Abstract

Factor X (factor ten) of the coagulation cascade binds to the integrin CD11b/CD18 during inflammation, initiating procoagulant activity on the surface of leukocytes (Altieri, D.C., O.R. Etingin, D.S. Fair, T.K. Brunk, J.E. Geltosky, D.P. Hajjar, and T. S. Edgington. 1991. Science [Wash.DC]. 254:1200-1202). Filamentous hemagglutinin (FHA), an adhesin of Bordetella pertussis also binds to the CD11b/CD18 integrin (Relman D., E. Tuomanen, S. Falkow, D.T. Golenbock, K. Saukkonen, and S.D. Wright. 1990. Cell. 61:1375-1382). FHA and the CD11b/CD18 binding loops of Factor X share amino acid sequence similarity. FHA peptides similar to Factor X binding loops inhibited 125I-Factor X binding to human neutrophils and prolonged clotting time. In addition, ETKEVDG and its Factor X analogue prevented transendothelial migration of leukocytes in vitro and reduced leukocytosis and blood brain barrier disruption in vivo. Interference with leukocyte migration by a coagulation-based peptide suggests a novel strategy for antiinflammatory therapy.

Item Type:Article
Source:Copyright of this article belongs to The American Society for Clinical Investigation, Inc.
ID Code:127804
Deposited On:12 Oct 2022 05:27
Last Modified:12 Oct 2022 05:27

Repository Staff Only: item control page